Ardelyx, Inc. (41X.F)

5,77 +0,09 (+1,54%) Ab 08:00AM CEST. Markt geöffnet.

Ardelyx, Inc.

400 Fifth Avenue
Suite 210
Waltham, MA 02451
United States
510 745 1700
https://www.ardelyx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 267

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael G. Raab	President, CEO & Director	968,4k	N/A	1965
Ms. Elizabeth A. Grammer Esq.	Chief Legal & Administrative Officer and Secretary	625,28k	N/A	1964
Dr. Laura A. Williams M.D., M.P.H.	Chief Medical Officer	622,06k	N/A	1964
Mr. Justin A. Renz CPA, MBA	Chief Financial & Operations Officer	583,6k	N/A	1972
Mr. Robert Felsch	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	N/A
Ms. Caitlin Lowie	Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Mike Kelliher	Executive Vice President of Corporate Development & Strategy	N/A	N/A	1977
Ms. Charon Spencer Sr.	Chief Human Resources Officer	N/A	N/A	N/A
Mr. David P. Rosenbaum	Chief Development Officer	603,9k	N/A	1961
Mr. Robert C. Blanks	Chief Regulatory Affairs & Quality Assurance Officer	552,81k	N/A	1960

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Ardelyx, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 6. Die grundlegenden Scores sind Audit: 4, Vorstand: 5, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.